Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 265-275

  Vickers, Steven P ^a   Cheetham, Sharon C ^a   Headland, Katie R ^a   Dickinson, Keith ^a   Grempler, Rolf ^b   Mayoux, Eric ^b   Mark, Michael ^b   Klein, Thomas ^b  

^a RenaSci Ltd   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Combination; Empagliflozin; Obesity; Rat; SGLT2; Sibutramine

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; INSULIN; LEPTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSURIA; GLYCEMIC CONTROL; IMPAIRED GLUCOSE TOLERANCE; LIPID COMPOSITION; MONOTHERAPY; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; RAT; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84903907128     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S58786     Document Type: Article

References (35)

1. World Health Organization. Obesity and overweight. Available from: http: //www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed March 15, 2014.
2. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010; 376(9754): 1775-1784.
3. Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol. 2009; 68(6): 861-874.
4. Jindal A, Brietzke S, Sowers JR. Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors. Cardiorenal Med. 2012; 2(4): 314-327.
5. Phung OJ, Scholle JM, Talwar M, etal. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303(14): 1410-1418.
6. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011; (120): S1-S6.
7. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12(6): 510-516.
8. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32(4): 650-657.
9. Bailey CJ. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis. 2010; 10(4): 193-199.
10. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011; 32(2): 63-71.
11. Grempler R, Thomas L, Eckhardt M, etal. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012; 14(1): 83-90.
12. Thomas L, Grempler R, Eckhardt M, etal. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012; 14(1): 94-96.
13. Dickinson K, North TJ, Anthony DM, Jones RB, Heal DJ. Evaluation of a simplified cafeteria model for the induction of insulin resistant obesity in rats. Int J Obes. 1998; 22 Suppl 3: S19.
14. Fisas A, Codony X, Romero G, etal. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol. 2006; 148(7): 973-983.
15. Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. 2011; 164(4): 1248-1262.
16. Häring HU, Merker L, Seewaldt-Becker E. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11): 3396-3404.
17. Kovacs CS, Seshiah V, Swallow R. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. Epub August 1, 2013.
18. Dickinson K, Mody N, Slater N, etal. The effect of chronic administration of sibutramine on body composition in dietary-induced, obese female Wistar rats-an evaluation of the Foss FoodScan™ analyser. 2008. Available from: http: //pa2online.org/abstract/abstract.jsp?abid=29118. Accessed March 15, 2014.
19. Dennis EA, Dengo AL, Comber DL, etal. Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity (Silver Spring). 2010; 18(2): 300-307.
20. James WP, Caterson ID, Coutinho W. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363(10): 905-917.
21. Hansen HH, Hansen G, Tang-Christensen M, etal. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010; 636(1-3): 88-95.
22. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996; 4(3): 263-270.
23. Gokcel A, Gumurdulu Y, Karakose H, etal. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002; 4(1): 49-55.
24. Sjöström L, Rissanen A, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998; 352(9123): 167-172.
25. Jackson HC, Dickinson K, Jones RB, Schumacher C, Jensen C. Comparison of the effects of sibutramine and orlistat on body weight, food and water intake and body composition in dietary-induced obese rats. Poster presented at: Society for Neuroscience Meeting; October 23-27, 2004; San Diego, CA.
26. Svendsen M, Helgeland M, Tonstad S. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. J Hum Nutr Diet. 2009; 22(1): 55-63.
27. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003; 115 Suppl 8A: 42S-48S.
28. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem. 2009; 20(11): 831-839.
29. Rodríguez A, Catalán V, Becerril S, etal. Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats. Life Sci. 2008; 83(15-16): 540-549.
30. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008; 327(1): 268-276.
31. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to type 2 diabetes: a review. Diabet Med. 2008; 25(10): 1142-1150.
32. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol. 1997; 121(8): 1613-1618.
33. Bolinder J, Ljunggren Ö, Kullberg J, etal. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. Clin Endocrinol Metab. 2012; 97(3): 1020-1031.
34. Ferrannini E, Berk A, Hantel S, etal. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36(12): 4015-4021.
35. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44(4): 375-393.